Compare Stocks: APLT, KVAC, INKT, and XLO

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APLT Applied Therapeutics	$0.10	$0.10	$0.09 ▼ $1.50	$14.36M	2.08	7.28 million shs	N/A
INKT MiNK Therapeutics	$12.00 -1.1%	$11.19	$8.48 ▼ $16.98	$61.24M	0.49	9,141 shs	42,352 shs
KVAC Keen Vision Acquisition	$11.51	$11.86	$11.41 ▼ $18.72	$63.38M	-0.04	14,430 shs	N/A
XLO Xilio Therapeutics	$8.93	$9.06	$6.47 ▼ $12.74	$58.76M	-0.14	10,500 shs	4,992 shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APLT Applied Therapeutics	0.00%	0.00%	0.00%	0.00%	-76.83%
INKT MiNK Therapeutics	0.00%	+3.09%	+9.09%	-0.17%	-21.52%
KVAC Keen Vision Acquisition	0.00%	0.00%	0.00%	-5.35%	-0.52%
XLO Xilio Therapeutics	0.00%	-0.78%	-0.89%	+7.46%	-13.94%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APLT Applied Therapeutics	$0.10	$0.10	$0.09 ▼ $1.50	$14.36M	2.08	7.28 million shs	N/A
INKT MiNK Therapeutics	$12.00 -1.1%	$11.19	$8.48 ▼ $16.98	$61.24M	0.49	9,141 shs	42,352 shs
KVAC Keen Vision Acquisition	$11.51	$11.86	$11.41 ▼ $18.72	$63.38M	-0.04	14,430 shs	N/A
XLO Xilio Therapeutics	$8.93	$9.06	$6.47 ▼ $12.74	$58.76M	-0.14	10,500 shs	4,992 shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APLT Applied Therapeutics	0.00%	0.00%	0.00%	0.00%	-76.83%
INKT MiNK Therapeutics	0.00%	+3.09%	+9.09%	-0.17%	-21.52%
KVAC Keen Vision Acquisition	0.00%	0.00%	0.00%	-5.35%	-0.52%
XLO Xilio Therapeutics	0.00%	-0.78%	-0.89%	+7.46%	-13.94%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APLT Applied Therapeutics	1.67	Reduce	$1.00	870.87% Upside
INKT MiNK Therapeutics	2.00	Hold	$35.00	191.67% Upside
KVAC Keen Vision Acquisition	2.00	Hold	N/A	N/A
XLO Xilio Therapeutics	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest APLT, KVAC, INKT, and XLO Analyst Ratings

Date	Company	Brokerage	Action	Rating
9/2/2026	XLO Xilio Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/12/2026	INKT MiNK Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/6/2026	XLO Xilio Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/29/2026	KVAC Keen Vision Acquisition	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C-) ➝ Hold (C)
7/17/2026	XLO Xilio Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/14/2026	INKT MiNK Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
7/8/2026	KVAC Keen Vision Acquisition	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C-)
7/6/2026	INKT MiNK Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/1/2026	XLO Xilio Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/17/2026	INKT MiNK Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/15/2026	XLO Xilio Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 9/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APLT Applied Therapeutics	$1M	15.86	N/A	N/A	$0.49 per share	0.21
INKT MiNK Therapeutics	N/A	N/A	N/A	N/A	($3.03) per share	N/A
KVAC Keen Vision Acquisition	N/A	N/A	N/A	N/A	N/A	N/A
XLO Xilio Therapeutics	$43.77M	1.34	N/A	N/A	$7.31 per share	1.22

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APLT Applied Therapeutics	-$105.62M	-$0.10	N/A	N/A	N/A	N/A	-340.84%	-175.00%	N/A
INKT MiNK Therapeutics	-$12.49M	-$2.40	N/A	N/A	N/A	N/A	N/A	-92.37%	11/12/2026 (Estimated)
KVAC Keen Vision Acquisition	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
XLO Xilio Therapeutics	-$35.04M	-$1.64	N/A	N/A	N/A	-34.06%	-71.99%	-20.43%	11/5/2026 (Estimated)

Latest APLT, KVAC, INKT, and XLO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	KVAC Keen Vision Acquisition	N/A	$0.08	N/A	$0.08	N/A	N/A
8/13/2026	Q2 2026	INKT MiNK Therapeutics	-$0.60	-$0.62	-$0.02	-$0.62	N/A	N/A
8/13/2026	Q2 2026	XLO Xilio Therapeutics	-$0.59	-$0.33	+$0.26	-$0.33	$12.72 million	$18.69 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
APLT Applied Therapeutics	N/A	N/A	N/A	N/A	N/A
INKT MiNK Therapeutics	N/A	N/A	N/A	N/A	N/A
KVAC Keen Vision Acquisition	N/A	N/A	N/A	N/A	N/A
XLO Xilio Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APLT Applied Therapeutics	N/A	0.96	0.96
INKT MiNK Therapeutics	N/A	1.23	1.23
KVAC Keen Vision Acquisition	N/A	N/A	N/A
XLO Xilio Therapeutics	N/A	4.25	4.25

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APLT Applied Therapeutics	98.31%
INKT MiNK Therapeutics	2.87%
KVAC Keen Vision Acquisition	51.72%
XLO Xilio Therapeutics	54.29%

Insider Ownership

Company	Insider Ownership
APLT Applied Therapeutics	1.60%
INKT MiNK Therapeutics	20.40%
KVAC Keen Vision Acquisition	80.20%
XLO Xilio Therapeutics	7.45%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APLT Applied Therapeutics	30	153.96 million	151.50 million	Optionable
INKT MiNK Therapeutics	30	5.10 million	4.06 million	No Data
KVAC Keen Vision Acquisition	N/A	5.51 million	1.09 million	Not Optionable
XLO Xilio Therapeutics	70	6.58 million	6.09 million	Not Optionable

APLT, KVAC, INKT, and XLO Headlines

Recent News About These Companies

Agios Pharmaceuticals (NASDAQ:AGIO) and Xilio Therapeutics (NASDAQ:XLO) Head to Head Survey

September 4, 2026 | americanbankingnews.com

Xilio Therapeutics Grants Inducement Stock Options to New Employees Under 2022 Plan

September 2, 2026 | quiverquant.comQ

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 2, 2026 | globenewswire.com

Stonepine Capital Management LLC Purchases 161,832 Shares of Xilio Therapeutics, Inc. $XLO

August 28, 2026 | marketbeat.com

Short Interest in Xilio Therapeutics, Inc. (NASDAQ:XLO) Expands By 58.8%

August 18, 2026 | marketbeat.com

Xilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business Updates

August 12, 2026 | globenewswire.com

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 6, 2026 | markets.businessinsider.com

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 6, 2026 | globenewswire.com

Xilio Therapeutics, Inc.: Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer

June 29, 2026 | finanznachrichten.de

Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer

June 29, 2026 | globenewswire.com

Xilio Therapeutics Inc

June 2, 2026 | edition.cnn.com

Cancer Stocks That Are Advancing the Future of Oncology Care

May 18, 2026 | zacks.com

Xilio Therapeutics, Inc. (XLO) Reports Q1 Loss, Beats Revenue Estimates

May 12, 2026 | zacks.com

Xilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and Business Updates

May 12, 2026 | globenewswire.com

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 7, 2026 | globenewswire.com

Xilio Therapeutics (XLO) price target decreased by 28.57% to 20.40

April 28, 2026 | msn.com

Xilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.2

April 17, 2026 | globenewswire.com

Xilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D. to its Board of Directors

April 16, 2026 | markets.businessinsider.com

Xilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D.

April 16, 2026 | globenewswire.com

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 3, 2026 | globenewswire.com

Xilio Therapeutics (XLO) Upgraded to Buy: What Does It Mean for the Stock?

April 1, 2026 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

APLT, KVAC, INKT, and XLO Company Descriptions

Applied Therapeutics NASDAQ:APLT

$0.10 0.00 (0.00%)

As of 09/11/2026

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.

MiNK Therapeutics NASDAQ:INKT

$12.00 -0.13 (-1.07%)

Closing price 09/11/2026 03:49 PM Eastern

Extended Trading

$12.60 +0.60 (+4.98%)

As of 09/11/2026 07:55 PM Eastern

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.

Keen Vision Acquisition NASDAQ:KVAC

$11.51 0.00 (0.00%)

As of 09/11/2026

Keen Vision Acquisition Corporation does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, and related business combination with one or more businesses or entities. It also intends to focus on businesses in the biotechnology, consumer goods, and agriculture sectors. The company was incorporated in 2021 and is based in Summit, New Jersey.

Xilio Therapeutics NASDAQ:XLO

$8.93 0.00 (0.00%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$9.09 +0.16 (+1.74%)

As of 09/11/2026 06:59 PM Eastern

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest APLT, KVAC, INKT, and XLO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest APLT, KVAC, INKT, and XLO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

APLT, KVAC, INKT, and XLO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

APLT, KVAC, INKT, and XLO Company Descriptions

Applied Therapeutics NASDAQ:APLT

MiNK Therapeutics NASDAQ:INKT

Keen Vision Acquisition NASDAQ:KVAC

Xilio Therapeutics NASDAQ:XLO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest APLT, KVAC, INKT, and XLO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest APLT, KVAC, INKT, and XLO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

APLT, KVAC, INKT, and XLO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

APLT, KVAC, INKT, and XLO Company Descriptions

Applied Therapeutics NASDAQ:APLT

MiNK Therapeutics NASDAQ:INKT

Keen Vision Acquisition NASDAQ:KVAC

Xilio Therapeutics NASDAQ:XLO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools